A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis

Recruiting now · Phase 1 · Has a placebo group

Conditions studied: Rheumatoid Arthritis (RA)

In brief

The purpose of this study is to evaluate how well LY4213663 is tolerated and what side effects may occur in healthy participants and participants with rheumatoid arthritis (RA). The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last approximately 33 weeks excluding screening.

Key facts

Study ID
NCT07258849
Run by
Eli Lilly and Company
People needed
141
Starts
2025-12-02
Expected to finish
2028-03-01
Last updated by the study team
2026-06-23

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.